Pediatric Hematology/Oncology

Cardiotoxicity

Questions discussed in this category

At what cumulative anthracycline dose is it recommended to use dexrazoxane for cardioprotection?

2 Answers available

How would you manage metastatic alveolar soft part sarcoma in an young patient failing TKI?

How do you incorporate PD-L1 blockade?

1 Answer available

Papers discussed in this category

The Cochrane database of systematic reviews, 2011 Jun 15

Cardioprotective interventions for cancer patients receiving anthracyclines.

JACC. CardioOncology, 2019 Sep 24

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

JACC. CardioOncology, 2024 Apr 16

Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: : CardioOncology Controversies in Cardio-Oncology.

JACC. CardioOncology, 2023 May 02

The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer.

Heart failure reviews, 2025 Feb 17

The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.

The Lancet. Oncology, 2019-06

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

Related Topics in Pediatric Hematology/Oncology